For anyone (like me) who's spent years explaining that polycystic ovary syndrome isn't only about cysts on the ovaries, this one's for you. After more than a decade of debate, surveys, international workshops, and (yes) actual shouting matches at medical conferences, PCOS has officially been renamed. The new name is PMOS: polyendocrine metabolic ovarian syndrome.
The new name for PCOS: meet PMOS
The announcement came in May 2026, published in The Lancet and presented at the European Congress of Endocrinology. It might look like a single letter swap, but this change represents a fundamental shift in how the medical world understands a condition that affects millions of women. And it didn't happen on a whim. Nearly 22,000 stakeholders — patients, doctors, researchers, and advocates from around the globe — weighed in over the course of the process. When it came to the final vote, 87 out of 90 expert stakeholders said yes.
The full transition is expected to take about three years, but the new name is here. And it matters more than you might think.
Why the PCOS name change was long overdue
Let's be honest: "polycystic ovary syndrome" was never the best name for this condition. It was scientifically inaccurate, misleading for patients, and gave doctors a narrow lens through which to view a complex, whole-body disorder.
The word "polycystic" implied that the hallmark of the condition was cysts on the ovaries. But those so-called cysts aren't even cysts at all; they're immature follicles. And plenty of people with the condition never develop them. Meanwhile, some people with perfectly polycystic-looking ovaries on an ultrasound don't have the syndrome at all.
This confusion had real consequences. Up to 13% of reproductive-age women are estimated to have the condition, yet according to the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, published in collaboration with health professionals and endorsed by 39 organizations worldwide, roughly 70% of those affected remain undiagnosed. Doctors routinely dismissed patients who didn't present with cysts on an ultrasound, even when metabolic symptoms — insulin resistance, unexplained weight gain, fatigue, irregular periods — were clearly present.
The old name also created stigma. The word "polycystic" made people feel broken, like their ovaries were riddled with something wrong. It focused attention on the wrong organ and the wrong problem, while the endocrine and metabolic chaos happening throughout the body went unaddressed. For a condition that dramatically increases the risk of type 2 diabetes, cardiovascular disease, and mental health challenges, calling it an ovarian problem was not just incomplete. It was harmful.
What PMOS actually means (and why it matters)
Each word in the new name was chosen carefully, and each one does real work.
Polyendocrine: This acknowledges that multiple hormone systems are involved — not just reproductive hormones like estrogen and progesterone, but also androgens, insulin, cortisol, and others. The condition disrupts the endocrine system broadly, and the name now reflects that.
Metabolic: This is arguably the most important addition. Insulin resistance, difficulty managing weight, and elevated risk for type 2 diabetes have always been core features of the condition, but the old name treated them like side effects. Putting "metabolic" in the name signals to clinicians and researchers alike that these issues deserve front-and-center attention.
Ovarian: The ovarian component stays because the condition does involve ovarian dysfunction, and it keeps the focus on the population most directly affected: women and people with ovaries.
Syndrome: This remains because PMOS is still a collection of symptoms and features rather than a single, clearly defined disease. No one test can diagnose it, and it shows up differently in different people.
Put it all together, and the new name paints a much more accurate picture of what's actually happening in the body: hormonal disruption across multiple systems, metabolic dysfunction, and ovarian involvement, all bundled into a syndrome that requires a comprehensive approach to care.
Rescripted survey data backs this up: respondents pointed to weight changes, insulin-sensitizing medications, and metabolic-style symptom management, right alongside cycle irregularity.
Wait, what about men? The debate that almost changed everything
One of the more surprising threads in the renaming process was the question of whether men should be included. Early research has suggested that men may experience a related condition involving hyperandrogenism, metabolic issues, and insulin resistance. Research examining metabolic features in male relatives of women with PCOS has found that fathers and brothers of affected women showed higher rates of insulin resistance and hormonal imbalances than the general male population.
Some experts pushed to drop the word "ovarian" entirely, arguing that the condition might not be exclusive to people with ovaries and that a more inclusive name could open up research pathways. But patient advocates pushed back, and hard. Their argument was straightforward: women are already medically underserved and chronically underdiagnosed for this condition. Diluting the focus now, before the female version is even properly understood and funded, would be a step backward.
The final decision was to keep "ovarian" in the name. If research eventually defines a clear male counterpart, it can be given its own name. But for now, the priority is the people who have been waiting decades for better care.
How the PCOS name change process actually worked
This wasn't a decision made over coffee by a handful of endocrinologists. The PMOS renaming process has been called the most robust disease-renaming effort in medical history, and the timeline backs that up.
It started in 2015 at a meeting in Sicily where experts gathered to discuss whether the name should change. According to accounts from attendees, the conversation quickly became heated — less of a polite academic discussion and more of a full-on argument about what the condition actually is and who gets to define it.
From there, the process became more structured. Three major international surveys were conducted between 2017 and 2025, collecting input from nearly 22,000 respondents across multiple countries and continents. Participants included patients, healthcare providers, researchers, and charity organizations. Workshops tested potential names with diverse groups to ensure cultural sensitivity and translatability.
Questions Women Are Asking
The top priorities that emerged from respondents were clear: avoid stigma, make the name easy to communicate, and ensure scientific accuracy. According to the 2026 report published in The Lancet detailing the full process, these three criteria guided every stage of the decision-making. The final vote was decisive, with 87 out of 90 stakeholders endorsing PMOS as the new name.
What this means for your diagnosis and treatment
If you've already been diagnosed with PCOS, take a breath. You now have PMOS. It's the same condition with a better, more accurate name. Your diagnosis is still valid, your symptoms are still real, and your treatment plan doesn't change overnight.
But the name shift signals something bigger than semantics. When a condition's name explicitly includes the word "metabolic," doctors are more likely to screen for metabolic issues from the start. That means earlier conversations about insulin resistance, glucose monitoring, and cardiovascular risk — things that many patients have had to fight to get their doctors to take seriously.
Here's what to expect practically:
Insurance codes and medical records will eventually be updated, though it will take time for administrative systems to catch up.
Your existing prescriptions and treatment protocols remain the same.
Research funding may shift to better reflect the metabolic and endocrine components of the condition, potentially leading to new treatment approaches.
The word "metabolic" in the name validates what many patients have been saying for years: the weight gain, fatigue, and insulin issues aren't side complaints. They're central features of the condition.
You're not being overdramatic. It's literally in the name now.
The pushback: not everyone is thrilled
No major change comes without criticism, and the PMOS transition is no exception. Some advocates and organizations have raised valid concerns about the practical implications of a name change, even one as overdue as this.
Patient organizations, authors, and nonprofits that have built their brands around "PCOS" now face the work of updating websites, educational materials, trademarks, and domain names. Books will need new editions. Social media accounts may need rebranding. All of that costs money and time.
Some critics have also pointed out the seemingly small scale of the change: all that effort for one letter? But the survey data tells a different story. According to the stakeholder surveys conducted during the renaming process, approximately 75% of respondents said that preserving the old acronym was not a priority. They wanted accuracy and reduced stigma, even if it meant starting fresh.
There's also some concern that if future research confirms a male version of the condition, the name might need to change again. But the committee's position is pragmatic: name the condition accurately for the people it affects now, and address future developments as they arise.
What happens next
The official rollout period is three years. During that time, medical organizations, patient groups, and healthcare providers will begin adopting PMOS terminology. Educational materials, research papers, clinical guidelines, and diagnostic codes will transition. It won't happen all at once, and you'll likely see both names used interchangeably for a while.
In the meantime, here's what you can do:
Start using the new name. It's more accurate, less stigmatizing, and better reflects what's actually happening in your body.
Share the update with friends, family, or anyone who's ever brushed off your symptoms as "just an ovary thing."
Bring it up at your next doctor's appointment. If your provider hasn't heard about the change yet, consider it an opportunity to educate (or forward them this article).
Know that this name change is more than branding. It's a signal that the medical community is finally catching up to what patients have known for years: this condition is bigger than ovaries, and it deserves to be treated that way.
Eleven years, 22,000 voices, and one letter that changes everything. PMOS isn't just a new acronym. It's a promise that the way this condition is understood, researched, and treated is finally moving in the right direction.
